Vitality Watch

Dossier clinicaltrials trial early 02-sep-2026
Small or early-phase human trial or pilot study

Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels

Key claim: A French double-blind placebo-controlled trial (PostWelLB) is testing whether 3 months of daily Humiome® Post LB postbiotic (340 mg) reduces self-reported stress (PSS-10) in adults aged 50–75 with moderate stress.

Abstract

The placebo-controlled, double blind parallel intervention trial “PostWelLB” aims to test whether 3 months of daily supplementation with the postbiotic product “Humiome® Post LB” (HPLB; 340 mg / day) can reduce self-reported stress (PSS10 questionnaire)- in an older (50 - 75 years; all genders) population in France.

Why this matters

A French double-blind placebo-controlled trial (PostWelLB) is testing whether 3 months of daily Humiome® Post LB postbiotic (340 mg) reduces self-reported stress (PSS-10) in adults aged 50–75 with moderate stress.

Source

Link

Briefing card

Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels
Stage: trial early · clinicaltrials · 02-sep-2026

A French double-blind placebo-controlled trial (PostWelLB) is testing whether 3 months of daily Humiome® Post LB postbiotic (340 mg) reduces self-reported stress (PSS-10) in adults aged 50–75 with moderate stress.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07471659

build build 880 · 2bcef25 · 2026-11-18